US 11,732,046 B2
Modified anti-PD-L1 antibody and methods and uses for treating a neurodegenerative disease
Ester Yoles, Beit-Gamliel (IL); Berit Olsen Krogh, Valby (DK); Allan Jensen, Valby (DK); Jan Egebjerg, Valby (DK); Carol David, Rehovot (IL); Kuti Baruch, Ness Ziona (IL); and Michal Eisenbach-Schwartz, Rehovot (IL)
Assigned to ImmunoBrain Checkpoint, Inc., Dover, DE (US); and Yeda Research and Development Co. Ltd., Rehovot (IL)
Filed by ImmunoBrain Checkpoint, Inc., Dover, DE (US); and Yeda Research and Development Co. Ltd., Rehovot (IL)
Filed on Apr. 5, 2021, as Appl. No. 17/222,370.
Application 17/222,370 is a continuation of application No. 16/852,508, filed on Apr. 19, 2020, granted, now 10,995,141.
Claims priority of provisional application 62/836,247, filed on Apr. 19, 2019.
Claims priority of application No. 19170438 (EP), filed on Apr. 19, 2019.
Prior Publication US 2021/0221893 A1, Jul. 22, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61P 25/00 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2827 (2013.01) [A61K 2039/505 (2013.01); C07K 2317/515 (2013.01); C07K 2317/56 (2013.01)] 19 Claims
OG exemplary drawing
 
1. A modified anti-Programmed Death Ligand 1 (PD-L1) antibody, comprising
a heavy chain comprising a heavy chain variable region including a CDR1 of SEQ ID NO: 3 or SEQ ID NO: 4, a CDR2 of SEQ ID NO: 5 or SEQ ID NO: 6, and a CDR3 of SEQ ID NO: 7 or SEQ ID NO: 8, and a heavy chain constant region of SEQ ID NO: 55; and
a light chain comprising a light chain variable region including CDR1 of SEQ ID NO: 10 or SEQ ID NO: 11, a CDR2 of SEQ ID NO: 12 or SEQ ID NO: 13 and a CDR3 of SEQ ID NO: 14 or SEQ ID NO 15.